share_log

Collegium Pharmaceutical Analyst Ratings

Collegium Pharmaceutical Analyst Ratings

Collegium 製藥分析師評級
Benzinga ·  2023/08/04 12:47
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/04/2023 — HC Wainwright & Co. Reiterates → Neutral
08/04/2023 41.7% Needham → $35 Reiterates Buy → Buy
05/30/2023 41.7% Needham → $35 Reiterates Buy → Buy
05/05/2023 41.7% Needham → $35 Reiterates → Buy
05/02/2023 21.46% Jefferies → $30 Assumes → Buy
04/19/2023 41.7% Needham → $35 Reiterates → Buy
02/24/2023 41.7% Needham → $35 Reiterates → Buy
02/08/2023 41.7% Needham → $35 Reiterates → Buy
01/05/2023 41.7% Needham $34 → $35 Maintains Buy
11/04/2022 37.65% Needham $36 → $34 Maintains Buy
08/08/2022 — HC Wainwright & Co. Downgrades Buy → Neutral
04/06/2022 45.75% Needham $34 → $36 Maintains Buy
02/22/2022 70.04% Piper Sandler $36 → $42 Maintains Overweight
02/15/2022 17.41% HC Wainwright & Co. $26 → $29 Maintains Buy
02/15/2022 37.65% Needham $28 → $34 Maintains Buy
11/15/2021 13.36% Needham $26 → $28 Maintains Buy
11/05/2021 5.26% Needham $32 → $26 Maintains Buy
08/06/2021 -10.93% Cantor Fitzgerald $30 → $22 Downgrades Overweight → Neutral
08/06/2021 29.55% Needham $34 → $32 Maintains Buy
08/06/2021 13.36% HC Wainwright & Co. $33 → $28 Maintains Buy
01/11/2021 33.6% HC Wainwright & Co. $29 → $33 Maintains Buy
11/09/2020 17.41% HC Wainwright & Co. $31 → $29 Maintains Buy
07/14/2020 -67.61% BWS Financial → $8 Initiates Coverage On → Sell
05/27/2020 — Guggenheim Initiates Coverage On → Neutral
05/08/2020 45.75% Needham $38 → $36 Maintains Buy
02/12/2020 41.7% Piper Sandler $27 → $35 Maintains Overweight
02/07/2020 21.46% Cantor Fitzgerald $24 → $30 Maintains Overweight
02/07/2020 53.85% Needham $36 → $38 Maintains Buy
01/08/2020 45.75% Needham $28 → $36 Maintains Hold
08/08/2019 -2.83% Cantor Fitzgerald $35 → $24 Reiterates → Overweight
05/03/2019 -6.88% HC Wainwright & Co. → $23 Assumes → Buy
04/12/2019 — Janney Montgomery Scott Assumes → Buy
03/20/2019 -10.93% SunTrust Robinson Humphrey → $22 Initiates Coverage On → Buy
08/09/2018 41.7% Cantor Fitzgerald $40 → $35 Maintains Overweight
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
08/04/2023 - HC Wainwright公司 重申 →中性
08/04/2023 41.7% 李約瑟 →$35 重申 購買→購買
2023年05月30日 41.7% 李約瑟 →$35 重申 購買→購買
05/05/2023 41.7% 李約瑟 →$35 重申 →購買
05/02/2023 21.46% 傑富瑞 →$30 假設 →購買
04/19/2023 41.7% 李約瑟 →$35 重申 →購買
02/24/2023 41.7% 李約瑟 →$35 重申 →購買
02/08/2023 41.7% 李約瑟 →$35 重申 →購買
01/05/2023 41.7% 李約瑟 $34→$35 維護 買
11/04/2022 37.65% 李約瑟 $36→$34 維護 買
2022/08/08 - HC Wainwright公司 評級下調 購買→中性
04/06/2022 45.75% 李約瑟 $34→$36 維護 買
02/22/2022 70.04% 派珀·桑德勒 $36→$42 維護 超重
02/15/2022 17.41% HC Wainwright公司 $26→$29 維護 買
02/15/2022 37.65% 李約瑟 $28→$34 維護 買
2021年11月15日 13.36% 李約瑟 $26→$28 維護 買
2021年11月05日 5.26% 李約瑟 $32→$26 維護 買
08/06/2021 -10.93% 康託·菲茨傑拉德 $30→$22 評級下調 超重→中性
08/06/2021 29.55% 李約瑟 $34→$32 維護 買
08/06/2021 13.36% HC Wainwright公司 $33→$28 維護 買
2021/11/01 33.6% HC Wainwright公司 $29→$33 維護 買
11/09/2020 17.41% HC Wainwright公司 $31→$29 維護 買
07/14/2020 -67.61% BWS金融 →$8 開始承保 →銷售
05/27/2020 - 古根海姆 開始承保 →中性
05/08/2020 45.75% 李約瑟 $38→$36 維護 買
02/12/2020 41.7% 派珀·桑德勒 $27→$35 維護 超重
02/07/2020 21.46% 康託·菲茨傑拉德 $24→$30 維護 超重
02/07/2020 53.85% 李約瑟 $36→$38 維護 買
1/08/2020 45.75% 李約瑟 $28→$36 維護 保持
2019年08月08日 -2.83% 康託·菲茨傑拉德 $35→$24 重申 →超重
2019年05月03日 -6.88% HC Wainwright公司 →$23 假設 →購買
2019年4月12日 - 詹尼·蒙哥馬利·斯科特 假設 →購買
2019/03/20 -10.93% SunTrust Robinson Humphrey →$22 開始承保 →購買
2018年08月09日 41.7% 康託·菲茨傑拉德 $40→$35 維護 超重

What is the target price for Collegium Pharmaceutical (COLL)?

科萊姆製藥公司(Colcium Pharmtics)的目標價是多少？

The latest price target for Collegium Pharmaceutical (NASDAQ: COLL) was reported by HC Wainwright & Co. on August 4, 2023. The analyst firm set a price target for $0.00 expecting COLL to fall to within 12 months (a possible -100.00% downside). 11 analyst firms have reported ratings in the last year.

納斯達克公司(納斯達克代碼：COL)的最新目標價是由HC Wainwright&Co.於2023年8月4日報道的。這家分析公司將目標價定為0.00美元，預計Coll將在12個月內下跌(跌幅可能為-100.00%)。過去一年，有11家分析公司公佈了評級。

What is the most recent analyst rating for Collegium Pharmaceutical (COLL)?

科萊姆製藥公司(Coll)最近的分析師評級是多少？

The latest analyst rating for Collegium Pharmaceutical (NASDAQ: COLL) was provided by HC Wainwright & Co., and Collegium Pharmaceutical reiterated their neutral rating.

納斯達克(代碼：COL)的最新分析師評級由HC Wainwright&Co.提供，科大藥業重申其中性評級。

When is the next analyst rating going to be posted or updated for Collegium Pharmaceutical (COLL)?

科萊姆製藥(Coll)的下一次分析師評級將於何時發佈或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Collegium Pharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Collegium Pharmaceutical was filed on August 4, 2023 so you should expect the next rating to be made available sometime around August 4, 2024.

分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與科萊姆製藥公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Colcium Pharmtics的上一次評級是在2023年8月4日提交的，所以你應該預計下一次評級將在2024年8月4日左右的某個時候公佈。

Is the Analyst Rating Collegium Pharmaceutical (COLL) correct?

分析師對科爾製藥(Colcium Pharmtics)的評級正確嗎？

While ratings are subjective and will change, the latest Collegium Pharmaceutical (COLL) rating was a reiterated with a price target of $0.00 to $0.00. The current price Collegium Pharmaceutical (COLL) is trading at is $24.70, which is out of the analyst's predicted range.

雖然評級是主觀的，並將發生變化，但最新的大學制藥(COL)評級被重申，目標價在0.00美元至0.00美元之間。科萊姆製藥公司目前的股價為24.70美元，超出了分析師的預測範圍。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論